Medical / Drug Development
Next-Gen Drugs for Cancer, Rare Diseases Accelerate
Chong Kun Dang recently announced plans to invest KRW 2.2 trillion in establishing a state-of-the-art biopharmaceutical complex research and development cluster in Baegot District, Siheung City. In May 2024, it established CKD USA, a U.S. subsidiary in Boston, as a global R&D hub, and in June 2022, it opened the Gen2C gene therapy research center at Seoul St. Mary's Hospital to develop treatments
2025.09.24
